New drug shows promise for boosting growth in kids with dwarfism

NCT ID NCT06164951

Completed Disease control Sponsor: QED Therapeutics, a BridgeBio company Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a daily oral drug called infigratinib in 114 children aged 3 to 18 with achondroplasia, the most common form of dwarfism. The goal was to see if it could safely increase their growth rate compared to a placebo. The trial is now complete, and results will show whether this drug can become a new treatment option.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Infigratinib (a daily oral drug)
What this could lead to: If it works, this could become a new treatment to help children with achondroplasia grow taller.
What could go wrong: This is a completed Phase 3 trial, but results are not yet public. The drug may not work better than placebo, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

achondroplasia bone disorder Dwarfism hereditary disease Mucopolysaccharidosis IV musculoskeletal system disorder osteochondrodysplasia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACHONDROPLASIA

Contacts and locations

Locations

QED Investigative Site

San Francisco, California, 94609, United States
QED Investigative Site

Aurora, Colorado, 80045, United States
QED Investigative Site

Baltimore, Maryland, 21287, United States
QED Investigative Site

Columbia, Missouri, 65212, United States
QED Investigative Site

Cincinnati, Ohio, 45229, United States
QED Investigative Site

Nashville, Tennessee, 37232, United States
QED Investigative Site

Madison, Wisconsin, 53792, United States
QED Investigative Site

Buenos Aires, Buenos Aires F.D., C1245AAM, Argentina
QED Investigative Site

Parkville, Victoria, 3052, Australia
QED Investigative Site

Edmonton, Alberta, T6G 2B7, Canada
QED Investigative Site

London, Ontario, N6A 5W9, Canada
QED Investigative Site

Ottawa, Ontario, K1H 8L1, Canada
QED Investigative Site

Montreal, Quebec, H3T 1C5, Canada
QED Investigative Site

Bron, 69677, France
QED Investigative Site

Paris, 75015, France
QED Investigative Site

Toulouse, 31059, France
QED Investigative Site

Rome, 00168, Italy
QED Investigative Site

Bergen, 5009, Norway
QED Investigative Site

Oslo, 0372, Norway
QED Investigative Site

Singapore, 229899, Singapore
QED Investigative Site

Málaga, 29010, Spain
QED Investigative Site

Vitoria-Gasteiz, 01008, Spain
QED Investigative Site

Bristol, BS2 8BJ, United Kingdom
QED Investigative Site

Glasgow, G51 4TF, United Kingdom
QED Investigative Site

London, SE1 7EH, United Kingdom
QED Investigative Site

Manchester, M13 9WL, United Kingdom
QED Investigative Site

Sheffield, S10 2TH, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.